• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. GlaxoSmithKline Announces US Filing For Mepolizumab

    GlaxoSmithKline Announces US Filing For Mepolizumab

  2. FDA Approves Injectable Form Of Glaxo's Benlysta

    FDA Approves Injectable Form Of Glaxo's Benlysta

  3. Global Pediatric Drugs and Vaccines Strategic Business Report 2017-2024: Focus on Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs & Others - Research and ...

    Global Pediatric Drugs and Vaccines Strategic Business Report 2017-2024: Focus on Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs & Others - Research and Markets

  4. Global Scleroderma Treatment Market to Grow at a CAGR of 7% by 2021 - Key Vendors are AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline & Pfizer - Research and Markets

    Global Scleroderma Treatment Market to Grow at a CAGR of 7% by 2021 - Key Vendors are AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline & Pfizer - Research and Markets

  5. Innoviva to Report First Quarter Financial Results on July 26 at 5:00 p.m. EDT

    Innoviva to Report First Quarter Financial Results on July 26 at 5:00 p.m. EDT

  6. Global Castration Resistant Prostate Cancer Treatment Market 2017-2021 with Astellas Pharma, Johnson & Johnson, Sanofi & Valeant Dominating - Research and Markets

    Global Castration Resistant Prostate Cancer Treatment Market 2017-2021 with Astellas Pharma, Johnson & Johnson, Sanofi & Valeant Dominating - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.